Screening for Perioperative Myocardial Infarction
For high-risk patients (≥65 years, RCRI ≥1, or elevated NT-proBNP/BNP), obtain daily troponin measurements for 48-72 hours postoperatively; for symptomatic patients or those with ECG changes, measure troponin immediately regardless of risk status.
Risk-Based Screening Algorithm
Who to Screen
Mandatory troponin surveillance 1:
- Age ≥65 years
- Age 45-64 with significant cardiovascular disease
- Revised Cardiac Risk Index (RCRI) score ≥1
- Elevated preoperative NT-proBNP or BNP
- Baseline cardiovascular risk >5% for death or MI at 30 days
- Undergoing vascular or intermediate-risk surgery
- Asymptomatic patients after low-risk surgery (Class III recommendation)
- Clinically stable patients without risk factors
Screening Protocol
Troponin measurement timing 1:
- Baseline: Preoperative measurement (to distinguish acute from chronic elevation)
- Postoperative Day 1: First measurement
- Postoperative Day 2: Second measurement
- Postoperative Day 3: Third measurement if prior elevations detected
Use either conventional fourth-generation or high-sensitivity troponin assays based on availability 4.
When to Measure Troponin Immediately
Class I indication 2:
- New ECG changes (ST-segment elevation/depression, T-wave changes)
- Chest pain typical of acute coronary syndrome
- Unexplained dyspnea
- Hemodynamic instability requiring support
Adjunctive Monitoring
ECG Monitoring
Postoperative 12-lead ECG 1:
- Obtain immediately postoperatively in recovery room
- Repeat on postoperative days 1 and 2
- 88% of ischemic ECG changes appear within first 15 minutes post-surgery
- ECG changes confer 2.2-fold increase in major cardiac complications
Intraoperative ST-segment monitoring 2:
- Class IIa for known CAD or vascular surgery patients
- Use computerized ST-segment analysis when available
- Class IIb for patients with single or multiple CAD risk factors
What NOT to Do
Avoid routine telemetry 1: Evidence too weak to support routine postoperative telemetry monitoring given resource costs and lack of proven benefit beyond troponin surveillance.
Do not use CK-MB alone 5, 6: Higher false-positive rates without improved sensitivity compared to troponin; elevated CK-MB without ECG changes or symptoms does not predict worse outcomes.
Clinical Significance
Why This Matters
65% of perioperative MIs are asymptomatic 1, occurring within 48 hours when analgesics mask ischemic symptoms. Without troponin surveillance, these events go undetected.
Mortality risk 1:
- Asymptomatic MI: 4-fold increased 30-day mortality (aOR 4.00)
- Symptomatic MI: 4.76-fold increased 30-day mortality
- MINS (myocardial injury after noncardiac surgery): 3.3-fold increased mortality
- MINS patients: 9.8% vs 1.1% mortality in those without injury
Interpreting Results
Troponin elevation indicates 4:
- Acute myocardial injury if rise and fall pattern present
- Requires clinical context: distinguish ischemic from non-ischemic causes
- Non-ischemic causes: pulmonary embolism, sepsis, acute heart failure, stroke
MINS definition 1: Peak troponin T ≥0.03 ng/mL (fourth-generation) believed due to myocardial ischemia, detected in 8% of at-risk surgical patients.
Common Pitfalls
- Screening low-risk patients: Wastes resources without clinical benefit 2, 3
- Single troponin measurement: Cannot distinguish acute from chronic elevation without baseline or serial values 4
- Relying on symptoms alone: Misses 65% of perioperative MIs 1
- Using only ECG: Poor correlation with troponin elevation; troponin superior for diagnosis 3
- Ignoring asymptomatic elevations: Carry same mortality risk as symptomatic events 1
Guideline Evolution
The 2017 Canadian guidelines 1 provide the strongest recommendation for routine troponin surveillance in high-risk patients, while the 2014 ACC/AHA guidelines 3 remain more conservative, noting uncertainty about routine screening. The 2024 ACC/AHA guidelines 4 acknowledge troponin surveillance effectiveness but emphasize that optimal MINS management remains uncertain. The most recent and comprehensive evidence supports the Canadian approach for high-risk patient identification and mortality reduction.